Irianiwati Irianiwati, Gurky Thela Calcarina, Anwar Sumadi Lukman, Bawono Rheza Gandi, Dwianingsih Ery Kus
Department of Anatomical Pathology, Faculty of Medicine, Public Health and Nursing, University Gadjah Mada/Sardjito General Hospital, Sekip, Yogyakarta 55281, Indonesia.
Surgery Department, Faculty of Medicine, Public Health and Nursing, University Gadjah Mada/Sardjito General Hospital, Sekip, Yogyakarta 55281, Indonesia.
Mol Clin Oncol. 2025 Jan 30;22(4):32. doi: 10.3892/mco.2025.2827. eCollection 2025 Apr.
Triple-negative breast cancer (TNBC) is highly aggressive and has a poor prognosis. TNBC is commonly reported in young women and often relapses quickly, exhibiting aggressive characteristics. It is also linked to a loss of function of BRCA1. Patients with BRCA mutations require different treatments because this tumor type is sensitive to platinum-based chemotherapy regimens and inhibitors of the poly (ADP ribose) polymerase. The present study aimed to investigate the prognostic significance of BRCA1 expression in Indonesian patients with TNBC. The study included 57 patients with TNBC. Epidermal growth factor receptor and cytokeratin 5/6 immunostaining were used to classify TNBC into basal-like and non-basal-like subtypes. The BRCA1 expression was also determined using immunohistochemistry. Pearson's Chi-square analysis and Fisher's exact test were used to examine correlations between variables. Kaplan-Meier method was used to analyze the survival rate. Patients with TNBC had an average age of 55.18±10.014; most of them were ≥50 years-old, had high-grade tumors (75.4%), and were in the advanced stages of cancer (82.5%). The majority had no specific type of cancer (78.9%), received non-platinum-based therapies (64.9%), had basal-like subtypes (72.9%), and were still alive (56.1%). Negative BRCA1 expression was higher (52.6%) than positive expression (47.4%) and correlated with advanced cancer stage (P=0.035). However, the BRCA1 expression was not correlated with other clinicopathological variables and the types of therapy. Survival analysis showed that the stage and BRCA1 expression acted as insignificant prognostic factors in patients with TNBC (P=0.091 and P=0.150). In the present study, negative BRCA1 expression was correlated with advanced stage but did not act as a prognostic factor in Indonesian patients with TNBC.
三阴性乳腺癌（TNBC）具有高度侵袭性，预后较差。TNBC常见于年轻女性，且常迅速复发，表现出侵袭性特征。它还与BRCA1功能丧失有关。携带BRCA突变的患者需要不同的治疗方法，因为这种肿瘤类型对铂类化疗方案和聚（ADP核糖）聚合酶抑制剂敏感。本研究旨在探讨BRCA1表达在印度尼西亚TNBC患者中的预后意义。该研究纳入了57例TNBC患者。采用表皮生长因子受体和细胞角蛋白5/6免疫染色将TNBC分为基底样和非基底样亚型。还使用免疫组织化学法测定BRCA1表达。采用Pearson卡方分析和Fisher精确检验来检验变量之间的相关性。采用Kaplan-Meier法分析生存率。TNBC患者的平均年龄为55.18±10.014岁；其中大多数年龄≥50岁，患有高级别肿瘤（75.4%），且处于癌症晚期（82.5%）。大多数患者没有特定的癌症类型（78.9%），接受非铂类治疗（64.9%），为基底样亚型（72.9%），且仍存活（56.1%）。BRCA1阴性表达（52.6%）高于阳性表达（47.4%），且与癌症晚期相关（P=0.035）。然而，BRCA1表达与其他临床病理变量及治疗类型无关。生存分析表明，分期和BRCA1表达在TNBC患者中并非显著的预后因素（P=0.091和P=0.150）。在本研究中，BRCA1阴性表达与晚期相关，但在印度尼西亚TNBC患者中并非预后因素。
